Stifel raised the firm’s price target on Vertex (VERX) to $52 from $41 and keeps a Buy rating on the shares following what the firm calls ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex’s Restructuring Goals and Financial ... the energy sector might look at some better-ranked stocks like PEDEVCO Corp. PED,Royal Vopak VOPKY and VAALCO Energy (EGY). While PEDEVCO and ...

From blue chip dividend stocks to industry-leading growth stocks, there are plenty of bargains in today's market if you know ...

Vertex VERX, a Zacks Rank #1 (Strong Buy), offers enterprise tax technology solutions for retail trade, wholesale trade, and manufacturing industries in the United States and internationally.

Vertex's diverse pipeline, including Casgevy for SCD, suzetrigine for chronic pain, and the vanzacaftor triple for CF, positions it for growth despite launch challenges. Casgevy's complex ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Moderna and Vertex Pharmaceuticals, two of the biggest biotechnology companies in Massachusetts by head count, will together receive more than $11 million in tax breaks from the state in exchange ...